Recruiting
Phase 2

MK-6916

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07862595

Conditions

Pain Management

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

MK-6916

Hydrocodone/acetaminophen (HB/APAP)

MK-6916 Placebo

Rescue Medication

Study Details

Brief summary:

Researchers are looking for new treatments for pain. While there are many approved treatments for pain, the treatments do not work well for everyone. People can also become addicted to certain pain medicines. Researchers designed a trial medicine called MK-6916 to treat pain.

The goal of the trial is to learn if at least 1 dose of MK-6916 works better than placebo to lessen pain. A placebo looks like the trial medicine but has no trial medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.

Conditions

Pain Management

Study ID

NCT07862595

Start date

Nov 2, 2026

Status verified date

Nov, 2026

Completion date

Jun 10, 2027

Anticipated

Primary completion date

Jun 10, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has a bunion and is scheduled to undergo a primary, unilateral bunionectomy that includes distal first metatarsal osteotomy (ie, Austin procedure) with internal fixation
  • Has a body mass index (BMI) of 18 to <40 kg/m\^2
  • Reports moderate or severe pain on the Pain Severity (Verbal Rating Scale) VRS and reports a pain score of ≥4 on the Numeric Pain Rating Scale (NPRS) (Brief Pain Inventory-Short Form \[BPI-SF\] "Pain Now" Item), within 2 to 9 hours of popliteal block discontinuation
  • Has bunionectomy under regional anesthesia using a Mayo block, popliteal sciatic block and monitored anesthesia care (MAC)

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any of the following conditions in the index joint:
  • Has a Type 3 deformity requiring a base wedge osteotomy
  • Requires a concomitant surgery such as hammertoe repair or arthrodesis (fusion of the index toe)
  • Has had a prior bunionectomy or other foot surgery on the index foot
  • Has a painful, comorbid condition in the index joint, such as arthritis, that could confound the participant's assessment of postsurgical pain
  • Has an acute or chronic painful physical condition, surgical history, or sensory abnormality that may confound the ability of the participant to assess postoperative pain in the index joint
  • Has a cardiac dysrhythmia (eg, atrial fibrillation), or known structural heart disease (eg, cardiomyopathy)
  • Has a personal history of Brugada syndrome or 2 or more unexplained syncopal events
  • Has a known first degree relative with 2 or more unexplained syncopal events, unexplained cardiac arrest, sudden cardiac death or Brugada syndrome
  • Has a diagnosis of sleep apnea or uses a home continuous positive airway pressure machine
  • Has a history of peptic ulcer disease or gastrointestinal bleeding
  • Has a history of allergy or adverse reaction to opioid(s), acetaminophen (APAP), midazolam, volatile anesthetics, propofol, rocuronium, vecuronium, sugammadex, lidocaine, ondansetron, and/or promethazine
  • Has a history of hepatitis or liver disease that has been active within the 12 months
  • Has a history of malignancy, ≤ 3 years prior, except for successfully treated nonmelanoma skin cancer, prostate cancer, or localized carcinoma in situ of the cervix

Study Design

Enrollment

380 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm 1: MK-6916 120 milligrams (mg)

Participants will receive MK-6916 120 mg every 12 hours (q12h) for 48 hours. Participants may receive rescue medication every 6 hours (q6h). Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

experimental: Arm 2: MK-6916 70 mg

Participants will receive MK-6916 70 mg every 12 hours (q12h) for 48 hours. Participants may receive rescue medication every 6 hours (q6h). Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

active comparator: Arm 3: hydrocodone 5 mg /acetaminophen 325 mg (HB/APAP)

Participants will receive hydrocodone 5 mg/acetaminophen 325 mg (HB/APAP) every 6 hours (q6h) for 48 hours. Participants may receive rescue medication q6h. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

placebo comparator: Arm 4: MK-6916 Placebo

Participants will receive MK-6916 placebo every 6 hours (q6h). Participants may receive rescue medication q6h for 48 hours. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

Interventions

MK-6916

120 mg or 70 mg oral tablet given every 12 hours (q12h) for 48 hours.

Hydrocodone/acetaminophen (HB/APAP)

Hydrocodone 5 mg/acetaminophen 325 mg given as oral capsule every 6 hours (q6h) for 48 hours.

MK-6916 Placebo

Placebo oral table given every 6 hours (q6h) for 48 hours

Rescue Medication

Participants requesting rescue medication may receive protocol-specified rescue medication. Rescue treatment consists of open-label oxycodone immediate release (IR) oral tablet 5 mg given every 6 hours (q6h) (given in 5 mg increments for a maximum dose of 10 mg q6h). Participants should be encouraged to wait 1 hour after administration of the first dose of oxycodone 5 mg before administering a second dose. Participants will be encouraged to refrain from receiving rescue medication during the first 90 minutes after the first dose of study intervention.

Primary outcome measure

  • Sum of the Pain Intensity Difference 0 to 48 Hours (SPID48) [ Time Frame: Up to approximately 48 hours ]

Central Contacts and Locations

Central contacts

Locations

Clinical Pharmacology of Miami ( Site 0718)

Recruiting

Miami, Florida, United States, 33172

Contacts

Study Coordinator

305-817-2900

ForCare Clinical Research ( Site 0705)

Recruiting

Tampa, Florida, United States, 33613

Contacts

Study Coordinator

813-264-2155

Atlanta Center for Medical Research ( Site 0708)

Recruiting

Atlanta, Georgia, United States, 30331

Contacts

Study Coordinator

404-881-5800

Gateway Clinical Trails, Llc ( Site 0701)

Recruiting

O'Fallon, Illinois, United States, 62269

Contacts

Study Coordinator

618-726-1160

Legent Orthopedic & Spine Hospital ( Site 0711)

Recruiting

Bellaire, Texas, United States, 77401

Contacts

Study Coordinator

713-367-8548

Memorial Hermann Village ( Site 0704)

Recruiting

Houston, Texas, United States, 77043

Contacts

Study Coordinator

281-369-5765

Futuro Clinical Trials ( Site 0703)

Recruiting

McAllen, Texas, United States, 78501

Contacts

Study Coordinator

956-999-8399

Endeavor Clinical Trials PA ( Site 0700)

Recruiting

San Antonio, Texas, United States, 78240

Contacts

Study Coordinator

210-503-9773

JBR Clinical Research ( Site 0702)

Recruiting

Salt Lake City, Utah, United States, 84107

Contacts

Study Coordinator

801-261-2000

More Information

Sponsor

Merck Sharp & Dohme LLC

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.